Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder
Interventions
DRUG

viral specific cytotoxic t-lymphocytes

CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.

Trial Locations (9)

10595

RECRUITING

New York Medical College, Valhalla

19104

RECRUITING

Children's Hospital of Pennsylvania, Philadelphia

21287

RECRUITING

Johns Hopkins, Baltimore

43205

RECRUITING

Nationwide Children's Hosptial, Columbus

46202

RECRUITING

Indiana University, Indianapolis

53226

RECRUITING

Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee

63130

RECRUITING

Washington University, St Louis

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

94158

RECRUITING

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Nationwide Children's Hospital

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

Indiana University

OTHER

collaborator

Children's Hospital Los Angeles

OTHER

lead

New York Medical College

OTHER

NCT03266640 - Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) | Biotech Hunter | Biotech Hunter